Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Aeruginosa Infection
Conditions
Pseudomonas Aeruginosa Infection
Trial Timeline
Feb 29, 2012 → Sep 18, 2013
NCT ID
NCT01315678About Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. is a phase 3 stage product being developed by Insmed for Pseudomonas Aeruginosa Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01315678. Target conditions include Pseudomonas Aeruginosa Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01315678 | Phase 3 | Completed |
Competing Products
8 competing products in Pseudomonas Aeruginosa Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 52 |
| tobramycin + tobramycin | Novartis | Phase 3 | 77 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 77 |
| TIS or TIP | Novartis | Approved | 85 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 76 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 30 |
| TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® | Viatris | Pre-clinical | 20 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 60 |